MedPath

Shenzhen Geno-Immune Medical Institute

Ownership
Private
Established
2015-04-28
Employees
-
Market Cap
-
Website

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Phase 1
Suspended
Conditions
Ovarian Cancer
Interventions
Biological: OC-EIEs
First Posted Date
2018-01-09
Last Posted Date
2018-07-31
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
20
Registration Number
NCT03393962
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

🇨🇳

Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

🇨🇳

Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

Engineered Immune Effectors Against Ovarian Cancer

Phase 1
Conditions
Ovarian Cancer
Interventions
Biological: OC-CTLs
First Posted Date
2017-12-05
Last Posted Date
2019-09-19
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
20
Registration Number
NCT03362606
Locations
🇨🇳

Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

🇨🇳

Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

Engineered Immune Effectors Against Cervical Cancer

Phase 1
Conditions
Cervical Cancer
Interventions
Biological: CC-EIEs
First Posted Date
2017-12-05
Last Posted Date
2019-09-19
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
20
Registration Number
NCT03362619
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

🇨🇳

Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

🇨🇳

Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Phase 1
Conditions
Ewing Sarcoma
Sarcoma
Osteoid Sarcoma
Interventions
Biological: Sarcoma-specific CAR-T cells
First Posted Date
2017-11-29
Last Posted Date
2020-06-11
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
20
Registration Number
NCT03356782
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Intervention of CAR-T Against Cervical Cancer

Phase 1
Conditions
Cervical Cancer
Interventions
Biological: Cervical cancer-specific CAR-T cells
First Posted Date
2017-11-29
Last Posted Date
2019-09-19
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
20
Registration Number
NCT03356795
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Antigen-specific T Cells Against Lung Cancer

Phase 1
Conditions
Lung Cancer
Interventions
Biological: Lung cancer-specific T cells
First Posted Date
2017-11-29
Last Posted Date
2019-09-19
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
20
Registration Number
NCT03356808
Locations
🇨🇳

Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China

🇨🇳

Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Intervention of Engineered Immune Effector T Cells Against Lung Cancer

Phase 1
Withdrawn
Conditions
Lung Cancer
NSCLC
Interventions
Biological: LC-CTLs
First Posted Date
2017-11-27
Last Posted Date
2018-03-27
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Registration Number
NCT03353428
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

Not Applicable
Conditions
Beta-Thalassemia
Interventions
Genetic: Gene-modified autologous stem cells
First Posted Date
2017-11-24
Last Posted Date
2017-11-30
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
20
Registration Number
NCT03351829
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector

Not Applicable
Conditions
Fanconi Anemia
Interventions
Genetic: Gene-modified autologous stem cells
First Posted Date
2017-11-24
Last Posted Date
2019-09-19
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
10
Registration Number
NCT03351868
Locations
🇨🇳

Beijing Children's Hospital, Beijing, Beijing, China

🇨🇳

Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China

🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Phase 1
Conditions
Human Papilloma Virus
Interventions
Biological: HPV-CTLs
First Posted Date
2017-11-24
Last Posted Date
2019-09-19
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Target Recruit Count
100
Registration Number
NCT03351855
Locations
🇨🇳

Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath